Found 5 hits Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase BTK' and Ligand = 'BDBM230145' Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230145
(US10106559, Comparative Example 76 | US10435415, E...)Show SMILES Cc1nc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1cnc2ccccc2c1=O)C(C)(C)O |(3.34,1.54,;1.8,1.54,;1.8,3.08,;.47,3.85,;.47,5.39,;1.8,6.16,;-.86,6.16,;-.86,3.08,;-2.33,3.56,;-3.23,2.31,;-4.77,2.15,;-5.39,.74,;-4.49,-.5,;-2.95,-.34,;-2.33,1.06,;-.86,1.54,;.47,.77,;.47,-.77,;-.86,-1.54,;-.86,-3.08,;.47,-3.85,;1.8,-3.08,;1.8,-1.54,;3.14,-.77,;3.14,-3.85,;3.14,-5.39,;4.47,-6.16,;5.8,-5.39,;7.14,-6.16,;8.47,-5.39,;8.47,-3.85,;7.14,-3.08,;5.8,-3.85,;4.47,-3.08,;4.47,-1.54,;-6.93,.74,;-7.7,-.59,;-8.47,.74,;-7.7,2.08,)| Show InChI InChI=1S/C31H27N5O3/c1-16-19(9-7-11-24(16)36-15-33-22-10-6-5-8-21(22)30(36)38)25-17(2)34-28(29(32)37)27-26(25)20-13-12-18(31(3,4)39)14-23(20)35-27/h5-15,35,39H,1-4H3,(H2,32,37) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.90 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230145
(US10106559, Comparative Example 76 | US10435415, E...)Show SMILES Cc1nc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1cnc2ccccc2c1=O)C(C)(C)O |(3.34,1.54,;1.8,1.54,;1.8,3.08,;.47,3.85,;.47,5.39,;1.8,6.16,;-.86,6.16,;-.86,3.08,;-2.33,3.56,;-3.23,2.31,;-4.77,2.15,;-5.39,.74,;-4.49,-.5,;-2.95,-.34,;-2.33,1.06,;-.86,1.54,;.47,.77,;.47,-.77,;-.86,-1.54,;-.86,-3.08,;.47,-3.85,;1.8,-3.08,;1.8,-1.54,;3.14,-.77,;3.14,-3.85,;3.14,-5.39,;4.47,-6.16,;5.8,-5.39,;7.14,-6.16,;8.47,-5.39,;8.47,-3.85,;7.14,-3.08,;5.8,-3.85,;4.47,-3.08,;4.47,-1.54,;-6.93,.74,;-7.7,-.59,;-8.47,.74,;-7.7,2.08,)| Show InChI InChI=1S/C31H27N5O3/c1-16-19(9-7-11-24(16)36-15-33-22-10-6-5-8-21(22)30(36)38)25-17(2)34-28(29(32)37)27-26(25)20-13-12-18(31(3,4)39)14-23(20)35-27/h5-15,35,39H,1-4H3,(H2,32,37) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.90 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9714234 (2017)
BindingDB Entry DOI: 10.7270/Q2474CW0 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230145
(US10106559, Comparative Example 76 | US10435415, E...)Show SMILES Cc1nc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1cnc2ccccc2c1=O)C(C)(C)O |(3.34,1.54,;1.8,1.54,;1.8,3.08,;.47,3.85,;.47,5.39,;1.8,6.16,;-.86,6.16,;-.86,3.08,;-2.33,3.56,;-3.23,2.31,;-4.77,2.15,;-5.39,.74,;-4.49,-.5,;-2.95,-.34,;-2.33,1.06,;-.86,1.54,;.47,.77,;.47,-.77,;-.86,-1.54,;-.86,-3.08,;.47,-3.85,;1.8,-3.08,;1.8,-1.54,;3.14,-.77,;3.14,-3.85,;3.14,-5.39,;4.47,-6.16,;5.8,-5.39,;7.14,-6.16,;8.47,-5.39,;8.47,-3.85,;7.14,-3.08,;5.8,-3.85,;4.47,-3.08,;4.47,-1.54,;-6.93,.74,;-7.7,-.59,;-8.47,.74,;-7.7,2.08,)| Show InChI InChI=1S/C31H27N5O3/c1-16-19(9-7-11-24(16)36-15-33-22-10-6-5-8-21(22)30(36)38)25-17(2)34-28(29(32)37)27-26(25)20-13-12-18(31(3,4)39)14-23(20)35-27/h5-15,35,39H,1-4H3,(H2,32,37) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230145
(US10106559, Comparative Example 76 | US10435415, E...)Show SMILES Cc1nc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1cnc2ccccc2c1=O)C(C)(C)O |(3.34,1.54,;1.8,1.54,;1.8,3.08,;.47,3.85,;.47,5.39,;1.8,6.16,;-.86,6.16,;-.86,3.08,;-2.33,3.56,;-3.23,2.31,;-4.77,2.15,;-5.39,.74,;-4.49,-.5,;-2.95,-.34,;-2.33,1.06,;-.86,1.54,;.47,.77,;.47,-.77,;-.86,-1.54,;-.86,-3.08,;.47,-3.85,;1.8,-3.08,;1.8,-1.54,;3.14,-.77,;3.14,-3.85,;3.14,-5.39,;4.47,-6.16,;5.8,-5.39,;7.14,-6.16,;8.47,-5.39,;8.47,-3.85,;7.14,-3.08,;5.8,-3.85,;4.47,-3.08,;4.47,-1.54,;-6.93,.74,;-7.7,-.59,;-8.47,.74,;-7.7,2.08,)| Show InChI InChI=1S/C31H27N5O3/c1-16-19(9-7-11-24(16)36-15-33-22-10-6-5-8-21(22)30(36)38)25-17(2)34-28(29(32)37)27-26(25)20-13-12-18(31(3,4)39)14-23(20)35-27/h5-15,35,39H,1-4H3,(H2,32,37) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230145
(US10106559, Comparative Example 76 | US10435415, E...)Show SMILES Cc1nc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1cnc2ccccc2c1=O)C(C)(C)O |(3.34,1.54,;1.8,1.54,;1.8,3.08,;.47,3.85,;.47,5.39,;1.8,6.16,;-.86,6.16,;-.86,3.08,;-2.33,3.56,;-3.23,2.31,;-4.77,2.15,;-5.39,.74,;-4.49,-.5,;-2.95,-.34,;-2.33,1.06,;-.86,1.54,;.47,.77,;.47,-.77,;-.86,-1.54,;-.86,-3.08,;.47,-3.85,;1.8,-3.08,;1.8,-1.54,;3.14,-.77,;3.14,-3.85,;3.14,-5.39,;4.47,-6.16,;5.8,-5.39,;7.14,-6.16,;8.47,-5.39,;8.47,-3.85,;7.14,-3.08,;5.8,-3.85,;4.47,-3.08,;4.47,-1.54,;-6.93,.74,;-7.7,-.59,;-8.47,.74,;-7.7,2.08,)| Show InChI InChI=1S/C31H27N5O3/c1-16-19(9-7-11-24(16)36-15-33-22-10-6-5-8-21(22)30(36)38)25-17(2)34-28(29(32)37)27-26(25)20-13-12-18(31(3,4)39)14-23(20)35-27/h5-15,35,39H,1-4H3,(H2,32,37) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.90 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this
Ligand-Target Pair | |
Search and Browse
